May 31, 2022
Life Sciences
  • Next week a key Food and Drug Administration (FDA) advisory committee will examine Novavax’s application for an emergency use authorization for its COVID-19 vaccine for adults 18 and older. Novavax originally planned to ask FDA for authorization by May 2021 but ran into production problems and struggled to meet FDA standards. Even though approximately 77 percent of adults have received two doses of an mRNA shot, Novavax’s Chief Commercial Officer John Trizzino said he doesn’t see an issue with waning demand. He also said negotiations are ongoing about how many doses the government will purchase from the initial agreement. (Articles here and here)